Dublin, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Pneumococcal Vaccine Market 2016-2020" report to their offering.
This comprehensive report forecasts the global pneumococcal vaccine market to grow at a CAGR of 13.69% during the 2016-2020 period.
Pneumococcus (Streptococcus pneumoniae), a pathogenic bacterium, is the leading cause of serious illness worldwide. It is the major cause of pneumonia, blood infections, meningitis, sinusitis, and middle ear infections (otitis media). Pneumococcal infections affect children younger than five years and older people (65 years and older), and it is among the leading infectious disease. It kills almost 1.6 million people (including over 800,000 children under five years) every year. It can be prevented by vaccination and involves the introduction of a dead or weakened antigen into the human body. This produces lymphocytes to counter the infection and any future invasions by that antigen. The report states that inadequate vaccine coverage will be a challenge for the market. The coverage rates for a vaccine indicate the level of acceptance and extent of immunization for that vaccine. Negligence and lack of awareness among individuals, despite the subsidies offered by the government, is a major factor decreasing these coverage rates.
Studies have estimated that the total global PCV coverage was at 19% in 2014. Studies also say that the coverage was 20% among the adults aged 19-64 years in 2013 in the US. The vaccination rate was higher in the adults aged 65 years and above, which was reported at 59.9%. The overall rate for pneumococcus infection was around 17% among vaccine-eligible subjects. Questions Answered:
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Companies Mentioned:
- Pfizer
- Sanofi
- Merck
- GSK
- Abera
- AstraZeneca
- Baxter
- Beijing Minhai Biotechnology
- Biken
- Biogen
- Celgene
- Eli Lilly
- Genentech
- Genocea Biosciences
- ImmunoBiology
- Lupin
- Nuron Biotech
- Panacea Biotec
- S K Chemicals
- Serum Institute of India
- Sinovac
- Valneva Austria
Report Structure:
PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Pneumococcal vaccine: Overview PART 06: Market landscape PART 07: Geographical segmentation PART 08: Market drivers PART 09: Impact of drivers
PART 10: Market challenges PART 11: Impact of drivers and challenges
PART 12: Market trends PART 13: Vendor landscape PART 14: Appendix PART 15: About the Author
For more information about this report visit http://www.researchandmarkets.com/research/v4s6zt/global
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
